IjB kinase b (IKKb), a central coordinator of inflammation through activation of nuclear factor-jB, has been identified as a potential therapeutic target for the treatment of obesity-associated metabolic dysfunctions. In this study, we evaluated an antisense oligonucleotide (ASO) inhibitor of IKKb and found that IKKb ASO ameliorated diet-induced metabolic dysfunctions in mice. Interestingly, IKKb ASO also inhibited adipocyte differentiation and reduced adiposity in high-fat (HF)-fed mice, indicating an important role of IKKb signaling in the regulation of adipocyte differentiation. Indeed, CRISPR/Cas9-mediated genomic deletion of IKKb in 3T3-L1 preadipocytes blocked these cells differentiating into adipocytes. To further elucidate the role of adipose progenitor IKKb signaling in diet-induced obesity, we generated mice that selectively lack IKKb in the white adipose lineage and confirmed the essential role of IKKb in mediating adipocyte differentiation in vivo. Deficiency of IKKb decreased HF-elicited adipogenesis in addition to reducing inflammation and protected mice from diet-induced obesity and insulin resistance. Further, pharmacological inhibition of IKKb also blocked human adipose stem cell differentiation. Our findings establish IKKb as a pivotal regulator of adipogenesis and suggest that overnutrition-mediated IKKb activation serves as an initial signal that triggers adipose progenitor cell differentiation in response to HF feeding. Inhibition of IKKb with antisense therapy may represent as a novel therapeutic approach to combat obesity and metabolic dysfunctions. STEM CELLS 2016;34:1883-1895 
INTRODUCTION
Obesity is a rapidly growing epidemic representing a growing serious health threat in an increasing number of countries as the number of overweight and obese individuals are expected to increase to over half of the world's population by 2030 [1] . There is an urgent need to understand the mechanisms underlying obesity and obesity-related metabolic diseases. Obesity is associated with both increased adipocyte size (hypertrophy) and adipocyte number (hyperplasia). Adipocyte number is a major determinant of fat mass in adults [2, 3] and approximately 10% of the body's adipocytes are re-generated annually at all adult ages [3] . Obese individuals also have a significantly greater number of adipocytes added per year than lean individuals [2, 3] , suggesting that regulation of new adipocyte production is a potential therapeutic target to treat obesity. However, the mechanisms underlying nutritionally induced hyperplasia remain largely unknown.
It is generally accepted that obesity is associated with a state of chronic low-grade inflammation that is a major contributor to type 2 diabetes and atherosclerosis [4, 5] . Many inflammatory pathways that contribute to the pathogenesis of insulin resistance and atherosclerosis are regulated by the transcriptional factor nuclear factor-jB (NF-jB), a master regulator of the innate and adaptive immune responses [6] . IjB kinase (IKK) b is the predominant catalytic subunit of the IKK complex and is required for activation of NF-jB by inflammatory mediators in the canonical or classical activation pathway [6] [7] [8] [9] . It has been well established that overnutrition can lead to IKKb activation in vitro and in vivo [10] [11] [12] , and recent studies have implicated IKKb as a key molecular link between obesity, inflammation and metabolic disorders [5, 13, 14] . For example, diet-induced insulin resistance has been associated with the activation of IKKb/NF-jB in multiple tissues including liver, adipose tissue, and brain [10, [15] [16] [17] [18] [19] [20] . Deletion of IKKb in the liver improved diet-induced insulin resistance, and deficiency of IKKb in myeloid cells rendered global insulin sensitivity upon high-fat (HF) feeding [17] . By contrast, constitutive activation of IKKb in the liver caused systemic insulin resistance [18] . Activation of IKKb in the hypothalamus has also been linked to obesity and metabolic disease [19, 21] .
We have recently demonstrated that IKKb functions in smooth muscle cells (SMCs) to regulate vascular inflammatory responses and atherosclerosis development [8] . Of particular interest is that many adipocyte precursor cells express SMC markers and ablation of IKKb blocked adipocyte differentiation in vitro and in vivo, suggesting that IKKb functions in adipocyte precursor cells to regulate adipose tissue development [8] . In the present study, we explored a novel and efficient pharmacological approach to inhibit IKKb in vivo by using antisense oligonucleotides (ASOs) and found that ASOmediated IKKb knockdown ameliorated diet-induced obesity and metabolic disorders in mice. Interestingly, IKKb ASO also inhibited high-fat diet (HFD)-elicited adipocyte differentiation and reduced adipose tissue growth. As the functions of IKKb in regulating adipogenesis and adipose tissue development has not been fully understood, we then selectively deleted IKKb in the white adipose lineage in mice to further elucidate the role of adipose progenitor cell IKKb signaling in obesity and metabolic function. Deficiency of IKKb decreased adipogenesis and systemic inflammation elicited by HF feeding, leading to reduction in diet-induced obesity and insulin resistance. Last, inhibition of IKKb in human adipose stem cells also blocked adipogenesis in these cells. Our results establish IKKb as an important regulator of adipogenesis and adipose tissue development. Overnutrition-mediated IKKb activation may serve as an initial signal that triggers adipose progenitor cell differentiation in response to consumption of a HFD. Antisense therapy targeting IKKb may present as a novel therapeutic approach to combat obesity and metabolic dysfunctions.
MATERIALS AND METHODS

Animals
For the IKKb ASO studies, 8-week-old male C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME, http://www.jax.org/) were fed a normal chow diet (ND) or a Western-type HFD (21 
Metabolic Analyses
Body weight was measured weekly and body composition was measured by nuclear magnetic resonance (NMR) spectroscopy (Echo MRI, Houston, TX, http://www.echomri.com/). Intraperitoneal glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed, as previously described [8] . Plasma insulin was measured using a Rat/Mouse Insulin ELISA kit (Millipore, Billerica, Massachusetts, http://www.emdmillipore.com/US/ en). Plasma TNFa levels were measured by a mouse TNFa ELISA kit (BioLegend, San Diego, CA, http://www.biolegend.com/). Plasma cytokine levels were measured by a mouse cytokine multiplex assay kit and a BioPlex 200 system (Bio-Rad Laboratories, Hercules, California, http://www.bio-rad.com/). For insulin stimulation studies, 20-week-old male IKKb F/F and IKKb
DPDGFRb
littermates or ASO-treated C57BL/6 mice were injected with insulin (0.35 U/kg body weight) into the inferior vena cava [25] . After 5 minutes, mice were euthanized and tissues were collected for protein isolation and Western blot analysis.
Adipose Stromal Vascular (SV) Cell Isolation and Differentiation
Adipose SV cells and mature adipocytes were isolated as previously described [8] . The SV cells were used for RNA and protein isolation or cultured in 12-well plates for differentiation. For differentiation assays, SV cells were induced by high-glucose Dulbecco's modified Eagle's medium containing dexamethasone (1 lM), isobutylmethylxanthine (0.5 mM), insulin (10 lg/ml), rosiglitazone (1 lM), and 10% fetal bovine serum (FBS) until they were ready for analysis [8] .
RNA Isolation and Quantitative Real Time PCR (QPCR) Analysis
Total RNA was isolated from mouse tissues or cells using TRIzol Reagent (Life Technologies, Grand Island, NY, https://www.thermofisher.com/) and QPCR was performed using gene-specific primers and the SYBR Green PCR kit (Life Technologies) as previously described [26, 27] . The sequences of primer sets used in this study are listed in Supporting Information 
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Germantown, MD, http://www.qiagen.com). QPCR was performed on COX1 mitochondrial DNA and normalized to a nuclear 28S sequence [28, 29] . The sequences of primer sets used in this study are listed in Supporting Information Table 1 .
Human Subjects and Adipose Stem Cell Isolation
Human adipocytes were derived from the differentiation of adult-derived human adipose stem cells (ADHASC) as described previously [30, 31] . The adipose tissue was from a collagenase digestion of the lipoaspirate of patients undergoing liposuction of subcutaneous fat. These patients were generally young, healthy women undergoing cosmetic procedures, and this method of collection was approved by the University of Kentucky Institutional Review Board. Differentiation was induced using differentiation media as previously described [30, 31] . At least 80%-90% of the cells developed lipid droplets in 7-10 days.
Statistical Analysis
All data are presented as the mean 6 SEM. Individual pairwise comparisons were analyzed by two-sample, two-tailed Student's t test unless otherwise noted, with p < .05 was regarded as significant. Two-way analysis of variance (ANOVA) was used when multiple comparisons were made followed by a Bonferroni multiple comparisons test. N numbers are listed in figure legends.
RESULTS
ASO-Mediated IKKb Knockdown Protects Mice from Diet-Induced Obesity
We recently demonstrated that IKKb inhibitors can inhibit adipocyte differentiation in vitro and ameliorate diet-induced adiposity in mice [8] . To explore novel and more efficient pharmacological approaches for IKKb inhibition, we utilized second-generation ASO targeting technology [32] and investigated the impact of IKKb ASO on diet-induced obesity and metabolic disorders. Intraperitoneal delivery of ASO has been shown to reach a variety of tissues including liver and adipose tissue [33, 34] . Indeed, we found that IKKb ASO can efficiently decrease IKKb gene expression in multiple tissues including liver, skeletal muscle (Sk.M), and WAT at a dose of 25 mg/kg BW/week (Fig. 1A) . Interestingly, IKKb mRNA levels were not significantly altered in brown adipose tissue (BAT) by IKKb ASO treatment at this dose. Western blot analysis also confirmed the specific and efficient IKKb knockdown in tissues including liver and WAT as IKKa protein levels were not affected by IKKb ASO treatment (Fig. 1B) . We next determined whether IKKb ASO treatment can ameliorate diet-induced obesity. Groups of 8-week-old wildtype male mice were fed a ND or HFD and were treated with control ASO or IKKb ASO for 8 weeks (Fig. 1C) . HF-feeding increased body weight in mice treated with both control and IKKb ASOs. However, IKKb ASO treatment significantly decreased HFD-induced body weight gain and adiposity. While lean mass was slightly but significantly increased in IKKb ASOtreated mice, fat mass was decreased by 45% in HFD-fed mice treated with IKKb ASO (Fig. 1D) . IKKb ASO was able to decrease both subcutaneous (sub) WAT and visceral WAT including epididymal (epi) and retroperitoneal (retro) fat pads in HFD-fed mice as compared with littermate controls (Fig. 1E ).
IKKb ASO Improves Insulin Sensitivity and Reverses Hepatic Steatosis in Obese Mice
Obesity is frequently associated with metabolic disorders such as insulin resistance and hepatic steatosis. We next investigated whether IKKb ASO treatment can protect HFD-fed mice from these disorders. IKKb ASO-treated mice had decreased fasting plasma glucose and insulin concentrations as compared with control mice (Fig. 1F) , suggesting improved diabetic phenotype. Upon glucose and insulin tolerance test, IKKb ASO-treated mice had improved glucose tolerance and showed an increased hypoglycemic response to the injected insulin (Fig. 1G ). To further assess the impact of IKKb ASO treatment on insulin signaling, HFD-fed mice were injected with insulin prior to euthanization and phosphorylation of Akt was analyzed in multiple tissues. IKKb ASO was able to enhance phosphorylation of Akt in response to insulin in liver, Sk.M and WAT (Fig. 1H ). While hepatic IKKb signaling has been demonstrated to contribute to obesity-associated insulin resistance [17, 18] , the role of adipose IKKb signaling in the regulation of insulin sensitivity has not been well-defined. We then performed adipose glucose uptake assays. Interestingly, adipose tissue explants from IKKb ASOtreated mice had elevated glucose uptake in the absence of insulin and insulin stimulation further enhanced glucose update by adipose tissues (Fig. 1I) . Therefore, the enhanced Akt phosphorylation and increased glucose uptake in adipose tissue likely contribute to the improved insulin sensitivity in IKKb ASO-treated mice. Further, HF feeding also caused lipid accumulation and hepatic steatosis in control mice. However, IKKb ASO-treated mice were protected from these detrimental effects (Fig. 1J, 1K ). Consistently, hepatic triglyceride and cholesterol contents were significantly reduced in IKKb ASO-treated mice (Fig. 1L) . Collectively, these results suggest that pharmacological inhibition of IKKb by ASO ameliorates obesity-associated metabolic disorders in mice.
IKKb Regulates Murine Adipocyte Differentiation
We next investigated whether IKKb ASO treatment can also affect IKKb expression in adipocyte precursor cells and affect adipocyte differentiation. Indeed, we found that IKKb expression was decreased in both adipose SV cells and mature adipocytes in IKKb ASO-treated mice ( Fig. 2A) . Consistent with our previous study [8] , ASO-mediated IKKb knockdown diminished the ability of adipose SV cells to differentiate into adipocytes (Fig. 2B ). As expected, the expression levels of adipogenic genes including PPARg, Zfp423, and C/EBPs were significantly decreased in epiWAT from IKKb ASO-treated mice (Fig. 2C) . Further, IKKb ASO treatment also decreased the expression of a known NF-jB target, Smad ubiquitination regulatory factor 2 (Smurf 2) (Fig. 2D ). Smurf2 is an ubiquitin E3 ligase that regulates proteasome-mediated degradation of several proteins including b-catenin [8, 35, 36] . Consistently, ASO-mediated IKKb knockdown increased nuclear b-catenin protein levels in epi-WAT (Fig. 2E ). Since Wnt/b-catenin signaling has been well defined to inhibit adipogenesis in vitro and in vivo [37, 38] , the increased Wnt signaling likely contributes to the decreased adipogenesis in IKKb ASO-treated mice.
To further define the role of IKKb in adipogenesis, we used the CRISPR-Cas9 system to delete the IKKb gene in murine 3T3- L1 preadipocytes (Fig. 2F) . We found that deletion of IKKb almost completely blocked 3T3-L1 cell differentiation (Fig. 2G) . Gene expression analysis showed that mRNA levels of adipogenic genes and adipocyte markers including PPARg and adiponectin were significantly decreased by IKKb-deficiency (Fig. 2H) . Consistently, deletion of IKKb decreased the expression of Smurf2 (Fig. 2I ) and increased nuclear b-catenin accumulation (Fig. 2J) , leading to increased b-catenin activity in these cells ( Fig. 2K) . We further confirmed that b-catenin ubiquitination was inhibited by IKKb deficiency in 3T3-L1 cells (Fig. 2L) , suggesting the impact of reduced Smurf2 expression. Taken together, these results confirm the important role of IKKb in adipogenesis and indicate that pharmacological inhibition of IKKb by ASO can decrease adipogenesis and diet-induced adiposity.
Targeted Deletion of IKKb in the White Adipose Lineage
Since ASO treatment affects many tissues and cell types, it is not clear how significantly the ASO-mediated IKKb knockdown in adipose progenitors contributes to the beneficial effects on obesity and metabolic disorder in mice. Compared with other tissues or cell types, the role of IKKb signaling in adipose progenitors has not been well-defined. To investigate the function of IKKb signaling in adipose progenitors, we sought to generate a mouse model that selectively lacks IKKb in white adipose lineage. Recent studies have identified a subset of perivascular cells as adipose progenitors which express multiple mural cell markers including platelet-derived growth factor receptor (PDGFR) b, a smooth muscle actin, and NG2 [39] . For example, both PDGFRb, a human mesenchymal stem cell (MSC) marker [40] , and PDGFRa, another isoform of PDGFR, have been confirmed to be adipocyte progenitor markers by independent groups [41] [42] [43] [44] [45] . Consistently, we also found that the high expression levels of PDGFRb in adipose SV cells as compared with mature adipocytes (Supporting Information Fig. 1A ). We then crossed PDGFRb promoter-driven Cre mice [22] with Rosa26 lacZ reporter mice that express b-galactosidase (lacZ) in target tissues upon Cre-mediated excision of a "Stop" sequence to generate PDGFRb-Cre/Rosa26 lacZ mice (Supporting Information Fig. 1B Fig. 1C) . Staining of the white adipose depots and tissue sections also indicated that PDGFRb-Cre is activated in adipose progenitors that give rise to white adipocytes as PDGFRb generated strong lacZ expression in adipocytes in addition to the vasculature (Supporting Information Fig. 1D, 1E ). Taken together, our results are consistent with previous reports [39, 41] and confirm that PDGFRb is a marker for adipocyte lineage cells. We then deleted IKKb in adipocyte lineage cells by intercrossing PDGFRb-Cre mice with mice containing loxP-flanked (Fig. 3A) . As expected, PDGFRb-Cre-mediated IKKb deletion also caused reduced IKKb expression in adipose SV cells of IKKb DPDGFRb mice (Fig. 3B) . Further, IKKb deficiency reduces NF-jB-mediated pro-inflammatory gene expression in response to lipopolysaccharide (LPS) in adipose SV cells of IKKb DPDGFRb mice (Fig. 3C-3G ), suggesting impaired NF-jB activation in these cells.
Deficiency of IKKb in Adipocyte Lineage Cells Renders Mice Resistant to Diet-Induced Obesity
To determine the role of adipose progenitor IKKb signaling in obesity, IKKb (Fig. 4B) . HFD-fed IKKb DPDGFRb mice also had decreased visceral adipose pads including epididymal and retroperitoneal fat pads. However, deficiency of IKKb did not affect the size or weight of subWAT and BAT (Fig. 4C , Supporting Information Fig. 2A, 2B ). As subWAT often undergoes "browning" process which enhances oxidative metabolism and protects mice from metabolic dysfunctions [28, [46] [47] [48] , we then examined whether deficiency of IKKb affects browning of subWAT in these mice. Interestingly, the expression levels of beige or brown adipocyte markers as well as mitochondrial function-related genes such as UCP-1 and PGC-1a [28, 47, 48] were not affected in subWAT of IKKb DPDGFRb mice (Supporting Information Fig. 3A) . Consistently, IKKb DPDGFRb mice also had comparable mitochondrial content in subWAT as that of control littermates (Supporting Information Fig. 3B ). MRI analyses also confirmed that IKKb DPDGFRb mice had a significantly decreased volume of visceral adipose tissue but a similar subcutaneous adipose tissue volume as compared with IKKb F/F mice under HF feeding conditions (Fig. 4D, 4E ). We next analyzed the expression levels of IKKb and adipose progenitor markers in SV cells isolated from subWAT and epiWAT of control mice. Interestingly, IKKb expression levels were significantly higher in visceral SV cells than subcutaneous SV cells. Further, the expression levels of adipose progenitor markers such as PDGFRb were much higher in visceral SV cells as compared with subcutaneous SV cells (Supporting Information Fig. 4) , indicating a more abundant adipose progenitor cell population in visceral WAT. Collectively, these results demonstrate that PDGFRb-Cre-driven IKKb deficiency in the white adipose lineage decreases diet-induced obesity and visceral adiposity.
IKKb-Deficient Mice are Protected from ObesityAssociated Metabolic Disorders
We next investigated whether deficiency of IKKb also protected mice from obesity-associated insulin resistance. IKKb DPDGFRb mice had comparable glucose and insulin levels and similar glucose tolerance and insulin tolerance as that of IKKb F/F when fed a ND ( Fig. 5A , 5B; Supporting Information Fig. 5 ). As expected, HF feeding increased plasma glucose and insulin levels in both IKKb F/F and IKKb DPDGFRb mice (Fig. 5A ). Although glucose concentrations were not affected by IKKb deficiency, HFD-fed IKKb DPDGFRb mice had significantly decreased insulin concentrations as compared with HFD-fed control littermates (Fig. 5A) . Consistently, IKKb DPDGFRb mice also had improved glucose tolerance and insulin tolerance as compared with IKKb F/F mice under HF feeding conditions (Fig. 5B) . PDGFRb-Cre-mediated IKKb deletion also enhanced phosphorylation of Akt in response to insulin in WAT but not in liver and Sk.M (Fig. 5C) . Further, adipose tissue explants from IKKb DPDGFRb mice had significantly increased insulinstimulated glucose uptake compared with that of IKKb F/F mice (Fig. 5D) .
Obesity-associated macrophage infiltration contributes to the development of systemic insulin resistance [49] . Although IKKb expression levels were not affected in macrophages of IKKb DPDGFRb mice (Fig. 5E ), macrophage infiltration was substantially decreased in WAT of IKKb DPDGFRb mice (Fig. 5F , Supporting Information Fig. 6 ), suggesting that deficiency of IKKb in adipose lineage blocks the increased inflammatory infiltrates in WAT under obese conditions. Consistently, the mRNA levels of macrophage markers and several key proinflammatory cytokines including TNFa, MCP-1, and IL-1b were significantly decreased in WAT of IKKb DPDGFRb mice (Fig.  5G) . We next measured plasma cytokine levels to determine whether IKKb-deficient mice also had decreased systemic inflammation. Deficiency of IKKb significantly decreased HFDinduced plasma pro-inflammatory cytokines including TNFa, MCP-1 and IL-6 in IKKb DPDGFRb mice (Fig. 5H) . Taken together, deficiency of IKKb improved insulin signaling in adipose tissue and protected mice from obesity-associated metabolic disorders.
Deficiency of IKKb Inhibits Adipogenesis in Mice
We next investigated whether deficiency of IKKb can decrease HF feeding-elicited adipogenesis in vivo. For this experiment, IKKb F/F and IKKb DPDGFRb mice were treated with BrdU during the first week of HF feeding. We then used BrdU as a marker to track newly differentiated adipocytes in these mice after 7 days of HFD. Immunostaining of adipose tissue sections with BrdU antibodies revealed that IKKb DPDGFRb mice had significantly decreased BrdU positive adipocytes in WAT (Fig. 6A,  6B ), indicating decreased adipogenesis. We also assessed the adipogenic potential of adipose SV cells isolated from visceral adipose tissue of IKKb F/F and IKKb DPDGFRb mice and confirmed that IKKb deficiency impaired the adipogenic potential of SV cells from IKKb DPDGFRb mice (Fig. 6C) . Further, the expression levels of adipocyte markers and key adipogenic genes including PPARg, C/EBPa, and Zfp423, were significantly reduced by IKKb deficiency (Fig. 6D) . Consistent with results from IKKb ASO treatment and 3T3-L1 experiments (Fig. 3 ), IKKb DPDGFRb mice had decreased Smurf2 levels and increased nuclear b-catenin levels in epiWAT (Fig. 6E, 6F ) as well as in primary adipose SV cells (Fig. 6G, 6H) . Further, deficiency of IKKb substantially decreased b-catenin ubiquitination in adipose SV cells (Fig. 6I) , which likely contributes to the accumulation of nuclear b-catenin in IKKb DPDGFRb mice.
Inhibition of IKKb Decreases Adipogenesis in Human Adipose Stem Cells
In addition to murine 3T3-L1 preadipocytes and primary SV cells, we also determined whether IKKb regulates the differentiation of human adipose stem cells. Adult-derived human adipose stem cells, also known as ADHASCs [30, 31, 50] , were isolated from healthy subjects. Consistent with previous reports [30, 31, 50] , human adipose stem cells were able to efficiently differentiate into mature adipocytes in vitro and at least 80%-90% of the cells developed lipid droplets in 7-10 days (Fig. 7A) . Pharmacological inhibition of IKKb by BMS-345541 strongly inhibited human adipose stem cell differentiation and repressed human adipogenic gene expression (Fig. 7B) . BMS-345541 treatment also led to reduced Smurf2 expression and decreased b-catenin ubiquitination, leading to increased nuclear b-catenin levels ( Fig. 7C-7E ), which likely contribute to the decreased adipogenesis in human adipose stem cells. Collectively, these results demonstrated IKKb as an important regulator of both human and murine adipocyte differentiation.
DISCUSSION
As a central coordinator of inflammatory responses, IKKb signaling in multiple tissues including liver, pancreas, and brain have been associated with obesity and obesity-related metabolic dysfunctions [15, 17-19, 21, 51] . High doses of IKKb inhibitors such as salicylates have been used to treat inflammatory conditions including diabetes in humans for more than a century [52, 53] . Moreover, inhibition of IKKb activity by salicylates also protected mice against insulin resistance triggered by HFD or obesity [15, 16] . Interestingly, long-term anti-inflammatory therapy has also been associated with 
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weight loss in human studies [54] . We recently demonstrated that salicylates and the potent IKKb inhibitor, BMS-345541, can also inhibit adipocyte differentiation in a dose-dependent manner [8] . In the current study, we demonstrated that IKKb ASO can efficiently decrease IKKb expression in various tissues including liver and WAT, and ameliorate diet-induced obesity and metabolic disorders in mice. To our knowledge, our study is the first to use ASOs targeting IKKb in vivo and investigate its metabolic impact. Consistent with previous reports demonstrating that hepatic IKKb signaling contribute to insulin resistance [17, 18] , IKKb ASO-treated mice had improved insulin signaling in the liver. Nevertheless, knockdown of IKKb in WAT also resulted in enhanced Akt phosphorylation and increased glucose uptake. Therefore, the improved diabetic phenotype in IKKb ASO-treated mice was likely due to the repressed IKKb signaling in multiple tissues including liver and WAT. In addition to improved insulin signaling, IKKb ASO treatment also repressed IKKb expression in SV cells, leading to decreased adipogenesis in WAT. Collectively, our studies demonstrate IKKb as a potential target for future anti-obesity drugs and provide evidence for the use of appropriate IKKb ASOs as a potential therapeutic strategy to treat obesity and metabolic disease (Supporting Information Fig. 7 ). Despite substantial progress in defining transcription factors such as PPARg and C/EBPs in the regulation of committed preadipocyte differentiation, the initial signals that trigger adipose progenitor cells commitment to adipocyte lineage in response to overnutrition remain unknown. In addition to its well-established role as a central mediator of inflammation and immune responses, IKKb/NF-jB signaling plays key roles in the regulation of hematopoietic cell development and stem cell differentiation [36, [55] [56] [57] . It has also been reported that NF-jB activity increases during adipocyte differentiation [58] and IKKb/NF-jB activation is associated with increased adipogenesis and insulin resistance in maternal obesity [59] . Further, proinflammatory signals have been demonstrated to be important for adipogenesis in vivo and many IKKb/NF-jB activators including LPS, IL-1b, and MCP-1 can stimulate adipogenesis and promote adipocyte differentiation [60] [61] [62] . While the role of IKKb signaling in regulating HFD-elicited tissue inflammation and insulin resistance is well recognized [10, 13, 14] , it remained elusive if activation of IKKb also mediates adipogenesis and adipose tissue growth in response to overnutrition. Since ASOs affects many cell types, we then selectively deleted IKKb in white adipose lineage in mice and confirmed that deficiency of IKKb in adipocyte lineage cells decreased adipogenesis and systemic inflammation elicited by HF feeding, leading to resistance to diet-induced obesity and insulin resistance.
Intriguingly, IKKb
DPDGFRb mice displayed no significant phenotype under standard laboratory conditions but were resistant to obesity when challenged with a HFD, indicating that HFD-induced IKKb activation in adipose progenitors is essential for HFD-induced adipose tissue growth. Consistent with our previous report [8] , deficiency of IKKb significantly decreased Smurf 2 expression and substantially inhibited b-catenin ubiquitination in adipose SV cells, leading to accumulation of nuclear b-catenin and increased b-catenin activity. Wnt/b-catenin signaling plays an important role in the regulation of MSC lineage and has been well defined to inhibit adipogenesis in vitro and in vivo [37, 38, 63] . Consistently, Cre-mediated IKKb deletion or ASO-mediated IKKb knockdown impaired the adipogenic potential of adipose SV cells in mice. We also demonstrated, for the first time, that inhibition of IKKb activity can also block human adipose stem cells differentiation, suggesting that IKKb plays an important role in regulation of both murine and human adipocyte differentiation. 
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It is worth noting that IKKb
DPDGFRb mice had decreased visceral adipose tissue but comparable subcutaneous adipose tissue as control mice when fed a HFD. There is a major ontogenetic difference between visceral and subcutaneous fat as they have different developmental origins [64] . Wang et al. [46] demonstrated that different fat depots have extensive differences in adipogenic potential. Visceral adipose tissue has a high capacity for adipogenesis in vivo but subcutaneous adipogenesis is limited [46] . A recent study also confirmed that HF feeding rapidly and specifically activates adipogenesis in visceral but not subcutaneous depots in mice [65] . Further, subcutaneous fat depot can also undergo extensive browning process after cold exposure and the appearance brown-like cells or beige cells are mainly found in subcutaneous fat but not in visceral fat [46] . It has been recently demonstrated that the PDGFRb-positive adipocyte lineage cells contribute to beige adipogenesis after prolonged cold exposure [45] . While deficiency of IKKb did not affect the beige or brown adipocyte marker expression or mitochondrial content in subWAT of IKKb DPDGFRb mice after HF feeding, it would be of interest to investigate whether IKKb DPDGFRb mice have affected beige adipocyte formation or mitochondrial function after chronic cold exposure in the future. Consistent with previous studies demonstrating that human visceral adipose tissue expresses high levels of IKKb as compared with subcutaneous adipose tissue [66] , we also found that IKKb expression levels were significantly higher in murine visceral SV cells than in murine subcutaneous SV cells. Moreover, the expression levels of adipose progenitor markers including PDGFRb were much higher in visceral SV cells than in subcutaneous SV cells. It is plausible that visceral adipose tissue has more abundant adipose progenitor population and activation of IKKb signaling is required for these cells differentiating into adipocytes in response to HF feeding. Deletion of IKKb in adipocyte lineage cells therefore has more impact on visceral adipose tissue growth than that of subcutaneous adipose tissue when challenged with a HFD. Further studies will be required to determine the detailed mechanisms that account for the different effects of IKKb deficiency on visceral versus subcutaneous fat. While both subcutaneous and visceral fat are increased in obese mice and human, accumulation of visceral but not subcutaneous adipose tissue contributes to the increased risk of obesity-associated metabolic dysfunctions [67] . Our data suggest that targeting IKKb in adipocyte lineage cells may represent a novel therapeutic approach to reduce visceral adipose tissue mass in obesity.
CONCLUSION
Our study revealed a pivotal role of IKKb in the regulation of adipocyte differentiation and adipose tissue growth in obesity. ASO-mediated IKKb knockdown protected mice from dietinduced obesity and metabolic dysfunctions. Deficiency of IKKb in adipocyte lineage cells also inhibited HF feedingelicited adipocyte differentiation and adipose tissue growth, leading to resistance to obesity and insulin resistance. Our findings suggest that overnutrition-induced IKKb activation in adipose progenitors is an important trigger for adipocyte differentiation and IKKb antisense inhibition may represent as a novel therapeutic approach to combat obesity and related metabolic dysfunctions.
